Stocktoria
ImmunityBio, Inc. IBRX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2015-07-28
ImmunityBio, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622,000 | $240,000 | $934,000 |
| R&D expense | — | $190.1M | $232.4M | $248.1M | $196.0M |
| SG&A expense | — | $168.8M | $129.6M | $102.7M | $135.3M |
| Operating income | -$256.0M | -$344.2M | -$362.2M | -$351.3M | -$330.3M |
| Interest expense | $60.9M | $114.6M | $128.8M | $63.5M | $14.8M |
| Income tax | -$135,000 | $0 | -$40,000 | $34,000 | $9,000 |
| Net income | -$351.4M | -$413.6M | -$583.2M | -$416.6M | -$346.8M |
| EPS (diluted) | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 |
| Operating cash flow | -$304.9M | -$391.2M | -$366.8M | -$337.5M | -$274.4M |
| Free cash flow | -$308.8M | -$398.1M | -$397.3M | -$415.7M | -$308.0M |
| Cash & equivalents | $88.3M | $143.4M | $265.5M | $104.6M | $181.1M |
| Inventory | $910,000 | $8.3M | $0 | — | — |
| Total assets | $501.9M | $382.9M | $504.5M | $362.4M | $468.9M |
| Total liabilities | $1.0B | $871.1M | $1.1B | $812.2M | $712.8M |
| Shareholders' equity | -$500.5M | -$489.1M | -$587.0M | -$449.8M | -$243.9M |
Source: SEC EDGAR filings · CIK 0001326110 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.